Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
Rhea-AI Summary
Esperion (NASDAQ: ESPR) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 3:30 p.m. ET.
Investors can access a live webcast on Esperion's investor website; a replay will be available approximately two hours after the call and archived for about 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C, supported by the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is advancing next-generation ATP citrate lyase inhibitors (ACLYi) and pursuing commercial execution and international partnerships.
Positive
- None.
Negative
- None.
News Market Reaction – ESPR
In the Nov 19 session, ESPR declined 1.41%, reflecting a mild negative market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
